Southern cross Equities' Stuart Roberts bought out a very interesting report yesterday on the Biotech, pharmaceuticals and medical devices sectors. ACL cop a pretty good rap in this 48pg report.
A few ACL pieces:
1. Stuart says that the market is seriously undervaluing ACL due to delays in FDA approval of the company?s generic fonda.
2. Things SCE are looking out for:
- FDA approval of fondaparinux;
- First revenues from fondaparinux;
- Initiation of the HA-Irinotecan Phase III trial;
- Initiation of Phase II HA-Irinotecan study in small cell lung cancer
- Potential collaboration deals on VAST, and
- Pre-clinical data on interesting compounds generated by VAST.
3. They maintain their $2 price target with the $3.28 optimistic case and $1.98 base case.
- Forums
- ASX - By Stock
- TSN
- southern cross - biotech report
southern cross - biotech report
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add TSN (ASX) to my watchlist
(20min delay)
|
|||||
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
TSN (ASX) Chart |
Day chart unavailable